# US 10,501,540 B2 · Immunoglobulins binding human Vγ9 Vδ2 T cell receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,501,540 B2
- Document ID: US10501540B2
- Status: Granted
- Kind: B2
- Application number: 15/302,927
- Filed: 2015-04-10
- Published: 2017-02-02
- Granted: 2019-12-10
- Earliest claimed: 2014-04-10
- Assignees: Lava Therapeutics N.V.
- Applicants: Stichting VUmc
- Inventors: Johannes Jelle Van Der Vliet; Renée Cornelia Gerarda De Bruin; Tanja Denise De Gruijl; Hendrik Marinus Willem Verheul
- Web page: https://patentgrep.com/patent/US10501540B2

## CPC

- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- A61P 35/00: Antineoplastic agents
- C07K 16/30: from tumour cells
- A61K 2039/505: {comprising antibodies}
- C07K 2317/20: characterized by taxonomic origin
- C07K 2317/21: from primates, e.g. man
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/31: multispecific
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention is in the field of medicine and relates to immunology, and relates in particular to human Vγ9Vδ2 T cell receptor binding immunoglobulin molecules. Human Vγ9Vδ2 T cell receptor binding immunoglobulin molecules are in particular for use in medical treatment and/or useful in assays with human Vγ9Vδ2 T cells, wherein human Vγ9Vδ2 T cells may be modulated.

## Claims

### Claim 1

A human Vγ9Vδ2 T cell receptor binding immunoglobulin molecule, comprising a CDR1 region, and a CDR2 region,
and a CDR 3 region, wherein the CDR1, CDR2 and CDR3 regions comprise:
the amino acid sequences set forth in SEQ ID Nos: 4, 5 and 6, respectively, or
the amino acid sequences set forth in SEQ ID Nos: 7, 8 and 9, respectively, or
the amino acid sequences set forth in SEQ ID Nos: 4, 10 and 11, respectively, or
the amino acid sequences set forth in SEQ ID Nos: 12, 13 and 14, respectively, or
the amino acid sequences set forth in SEQ ID Nos: 15, 16 and 17, respectively, or
the amino acid sequences set forth in SEQ ID Nos: 18, 19 and 20, respectively, or
the amino acid sequences set forth in SEQ ID Nos: 18, 21 and 22, respectively, or
the amino acid sequences set forth in SEQ ID Nos: 23, 24 and 25, respectively, or
the amino acid sequences set forth in SEQ ID Nos: 15, 28 and 29, respectively, or
the amino acid sequences set forth in SEQ ID Nos: 31, 32 and 33, respectively, or
the amino acid sequences set forth in SEQ ID Nos: 31, 34 and 35, respectively, or
the amino acid sequences set forth in SEQ ID Nos: 44, 45 and 46, respectively.

### Claim 2 (depends on 1)

The immunoglobulin molecule according to claim 1, wherein the immunoglobulin molecule is a single chain antibody.

### Claim 3 (depends on 1)

The immunoglobulin molecule according to claim 1, wherein the immunoglobulin molecule is a single domain antibody.

### Claim 4 (depends on 1)

The immunoglobulin molecule according to claim 1, comprising one or more of the framework regions selected from the group of amino acid sequences of SEQ ID NOS. 67-70.

### Claim 5 (depends on 1)

The immunoglobulin molecule according to claim 1, wherein the immunoglobulin molecule has an amino acid sequence selected from the group of amino acid sequences consisting of SEQ ID NOS. 48-57, 59, 61, 62 and 66.

### Claim 6 (depends on 1)

A nucleotide sequence that encodes an immunoglobulin molecule according to claim 1.

### Claim 7 (depends on 6)

A host cell comprising a nucleotide sequence according to claim 6.

### Claim 8 (depends on 1)

Method for preparing an immunoglobulin molecule according to claim 1, comprising:
culturing a host cell comprising a nucleotide sequence that encodes the immunoglobulin molecule according to claim 1;
allowing the host cell to express the immunoglobulin;
obtaining the immunoglobulin.

### Claim 9 (depends on 1)

An immunoglobulin molecule according to claim 1, wherein the immunoglobulin molecule is an immunoglobulin molecule that activates human Vγ9Vδ2 T cells.

### Claim 10 (depends on 9)

The immunoglobulin molecule according to claim 9, wherein the immunoglobulin molecule is linked to an agent.

### Claim 11 (depends on 1)

The immunoglobulin molecule according to claim 1, which is a bispecific antibody comprising two single domain antibodies, the first single domain antibody comprising the CDR1, CDR2 and CDR3 regions as defined in claim 1, wherein the first single domain antibody is linked to a second single domain antibody wherein the second single domain antibody binds to a target.

### Claim 12 (depends on 1)

The immunoglobulin molecule according to claim 1, which is a bispecific antibody comprising two single domain antibodies, the first single domain antibody comprising the CDR1, CDR2 and CDR3 regions as defined in claim 1, wherein the first single domain antibody is linked to a second single domain antibody wherein the second single domain antibody binds to a cancer cell.

### Claim 13 (depends on 2)

The immunoglobulin molecule of claim 2, wherein the single chain antibody is a llama single chain antibody.

### Claim 14 (depends on 2)

The immunoglobulin molecule of claim 2, wherein the single chain antibody is a human single chain antibody.

### Claim 15 (depends on 3)

The immunoglobulin molecule of claim 3, wherein the single domain antibody is a llama single domain antibody.

### Claim 16 (depends on 3)

The immunoglobulin molecule of claim 3, wherein the single domain antibody is a human single domain antibody.